Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.

Experimental biology and medicine (Maywood, N.J.) - 1 Jul 2010

da Silva Glenda Nicioli, de Castro Marcondes João Paulo, de Camargo Elaine Aparecida, da Silva Passos Júnior Geraldo Aleixo, Sakamoto-Hojo Elza Tiemi, Salvadori Daisy Maria Fávero

Abstract excerpt

Currently, the combination of cisplatin and gemcitabine is considered a standard chemotherapeutic protocol for bladder cancer. However, the mechanism by which these drugs act on tumor cells is not completely understood. The aim of the present study was to investigate the effects of these two antineoplastic drugs on the apoptotic index and cell cycle kinetics of urinary bladder transitional carcinoma cell lines...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Cisplatin

Share to Deoxycytidine

Share to Gemcitabine

Share to Genes, p53

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 20558835
DOI: 10.1258/ebm.2010.009322

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.PMID 20558835Read ↗

Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.Semantic proximity Read ↗

Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53-mutated bladder cancer cells.Semantic proximity Read ↗

Cell cycle kinetics, apoptosis rates, DNA damage and TP53 gene expression in bladder cancer cells treated with allyl isothiocyanate (mustard essential oil).Semantic proximity Read ↗

Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.Semantic proximity Read ↗

Prima-1 induces apoptosis in bladder cancer cell lines by activating p53.Semantic proximity Read ↗

Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responsesSemantic proximity Read ↗

Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells.Semantic proximity Read ↗

Cell proliferation and cell cycle alterations in oesophageal p53-mutated cancer cells treated with cisplatin in combination with photodynamic therapy.Semantic proximity Read ↗

Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells.Semantic proximity Read ↗

The Histone Deacetylase Inhibitor Trichostatin A Synergistically Resensitizes a Cisplatin Resistant Human Bladder Cancer Cell LineSemantic proximity Read ↗

P53 reactivator PRIMA-1 MET synergizes with 5-Fluorouracil to induce apoptosis in pancreatic tumor cellsSemantic proximity Read ↗

p53 and chemosensitivity in bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.